Lost in translation: Treatment trials in the SOD1 mouse and in human ALS

@article{Benatar2007LostIT,
  title={Lost in translation: Treatment trials in the SOD1 mouse and in human ALS},
  author={Michael Benatar},
  journal={Neurobiology of Disease},
  year={2007},
  volume={26},
  pages={1-13}
}
  • M. Benatar
  • Published 1 April 2007
  • Medicine
  • Neurobiology of Disease
Therapeutic success in the superoxide dismutase (SOD1) mouse model of amyotrophic lateral sclerosis (ALS) has not translated into effective therapy for human ALS, calling into question the utility of such preclinical data for identifying therapeutic agents that are worthy of further study in humans. This random effects meta-analysis of treatment trials in the superoxide dismutase (SOD1) mouse was undertaken in order to explore possible reasons for this failure of translational research and to… 
Characterization of early pathogenesis in the SOD1G93A mouse model of ALS: part I, background and methods
TLDR
The rationale, approach, and methods for an extensive analysis of early changes that included an ultrastructural examination of central and peripheral components of the neuromuscular system in the SOD1G93A mouse and correlated these alterations with early muscle denervation, motor dysfunction, and motoneuron death are described.
Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis—Symptomatic Treatment Potential after Disease Onset
TLDR
Although treatment after symptom onset was less potent than treatment in asymptomatic animals, this study shows the therapeutic benefits of this well-tolerated substance, which is already in clinical use for other indications.
Modelling amyotrophic lateral sclerosis in mice
TLDR
The mouse models that are key for drug development in ALS are reviewed, the key features of each genetic subgroup are discussed, and how the models could be further developed to better model ALS is proposed to more effectively advance ALS drug discovery.
SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments
TLDR
The SOD1 and TDP-43 animal models created to date are summarised, report on recent findings supporting the potential mechanisms of ALS pathogenesis, and correlate this understanding with current developments in the clinic.
CDNF rescues motor neurons in three animal models of ALS by targeting ER stress
TLDR
It is identified that intracerebroventricular (i.c.v.) administration of CDNF significantly halts the progression of the disease and improves motor behavior in TDP43-M337V and SOD1-G93A rodent models of ALS.
New Insights on the Mechanisms of Disease Course Variability in ALS from Mutant SOD1 Mouse Models
TLDR
This review summarizes and discusses data obtained from the analysis of these two ALS mouse models under different aspects such as the motor phenotype, neuropathological alterations in the central nervous system and peripheral nervous system (PNS) and the motor neuron autonomous and non‐cell autonomous mechanisms with the aim of finding elements to explain the different rates of disease progression.
Redox Regulation and Misfolding of SOD1: Therapeutic Strategies for Amyotrophic Lateral Sclerosis
TLDR
Of the wide variety of therapeutic strategies currently being developed, therapeutic strategies that focus on the role of S OD1 in the pathology of ALS have been reviewed, including modification of cysteine 111, restoring SOD1 metal content and decreasing oxidative stress and immunization.
Translational Research in ALS
TLDR
The rapidly progressive disease course makes ALS a good testing ground for new therapies, and ALS offers the chance of proof-of-concept studies faster than other disorders.
Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis
TLDR
The major pathways associated with the pathology of ALS, the rodent models engineered to test efficacy of candidate drugs, the advancements being made in stem cell therapy for ALS, and what strategies may be important to circumvent the lack of successful translational studies in the clinic are reviewed.
Trials of Antidiabetic Drugs in Amyotrophic Lateral Sclerosis: Proceed with Caution?
TLDR
The role of pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, which failed to show efficacy in a recently published phase II clinical trial of ALS patients is discussed and its antidiabetic and antidyslipidemic effects might be detrimental.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 85 REFERENCES
The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies
  • M. Gurney
  • Medicine, Biology
    Journal of the Neurological Sciences
  • 1997
TLDR
It is shown that familial ALS mutations cause a gain-of-function in Cu,Zn SOD that enhances the generation of damaging oxygen radicals, which may render motor neurons sensitive to the excitotoxic effects of ambient glutamate, as a putative glutamatergic inhibitor such as riluzole has therapeutic efficacy both in the transgenic model and in human ALS.
The effect of leukaemia inhibitory factor on SOD1 G93A murine amyotrophic lateral sclerosis.
TLDR
The results show that LIF had no beneficial effects when administered using the three methods of drug delivery, and suggest that further evaluation of LIF in this transgenic model is required to fully characterize its' therapeutic potential.
Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis
TLDR
Results indicate that minocycline, which is clinically well tolerated, may represent a novel and effective drug for treatment of ALS.
Efficient three‐drug cocktail for disease induced by mutant superoxide dismutase
TLDR
Results indicate that a combination approach consisting of three drugs for distinct targets in the complex pathway to neuronal death, minocycline, riluzole, and nimodipine may represent an effective strategy for ALS treatment.
Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model
TLDR
These data are the first to show a substantial extension of survival in an animal model of a fatal, dominantly inherited neurodegenerative condition using RNAi and provide the highest therapeutic efficacy observed in this field to date.
Magnesium supplementation does not delay disease onset or increase survival in a mouse model of familial ALS
TLDR
It appears that a trial of oral Mg supplementation in human ALS is not warranted, and no difference in either time of onset of weakness, or survival, was seen in mutant SOD1 mice on different doses of Mg.
A therapeutic role for cyclooxygenase‐2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis
TLDR
This study provides the first experimental evidence that prophylactic treatment with COX‐2 inhibitors can significantly delay the onset of motor dysfunction in the SOD1‐G93A transgenic mouse model of ALS.
Therapeutic Benefits of Putrescine-Modified Catalase in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis
TLDR
Results support the role of free radical-mediated damage in the cascade of events leading to motor neurodegeneration in FALS and indicate that PUT-CAT interacts with a critical step in this cascade to delay the onset of clinical disease as well as the development of clinical weakness in F ALS transgenic mice.
Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid
TLDR
Treatment with Δ9‐tetrahydrocannabinol (Δ9‐THC) was effective if administered either before or after onset of signs in the ALS mouse model (hSODG93A transgenic mice), and in vitro, Δ9-THC was extremely effective at reducing oxidative damage in spinal cord cultures and anti‐excitotoxic in vitro.
Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy.
TLDR
It is shown that AVR-mediated GDNF expression delayed the onset of disease by 7 +/- 8 days, prolonged survival by 17 +/- 10 days, and delayed the decline in motor functions (as determined on a rotating rod) by 7-14 days.
...
1
2
3
4
5
...